Positive opinion on the use of Levemir® in children with type 1 diabetes aged two to five years
Today the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the extended use of Novo Nordisk's basal insulin analogue, insulin detemir, in children aged two to five years with type 1 diabetes. Data reviewed by the CHMP demonstrate that insulin detemir is an equally efficacious treatment option for two to five-year-old children with type 1 diabetes, compared with NPH. 
Novartis Group Company associates across 32 countries will participate in a new Novartis health and well-being initiative during the first Novartis Be Healthy Celebration Week from September 19-23, 2011. During the week, Novartis Group sites are offering many opportunities to help associates take control of their personal health. This includes providing information, activities and tips to promote health and help prevent future health issues. 
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that encouraging data on its investigational and approved medicines will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm being held 23-27 September 2011. Presentations include important new data on Roche's investigational antibody-drug conjugate trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer and pivotal data on vismodegib an investigational oral drug that targets a specific disease pathway in advanced skin cancer. 
GlaxoSmithKline (GSK) today announced that it has formed a long term strategic partnership with McLaren Group. The partnership, which will run initially until 2016, brings together two UK companies focused on innovation and high-tech research. Under the agreement, McLaren Group will share its widely acknowledged leading capabilities in engineering, technology, analytics, and strategy modelling, which it has developed over many years in its core business of Formula 1 motor sport, to help deliver world class performance across GSK's global businesses. 
Boehringer Ingelheim and the European Foundation for the Study of Diabetes (EFSD) today announced a new partnership to establish a €2.5 million research grant programme, encouraging diabetes research over the next three years. The EFSD/Boehringer Ingelheim European Research Programme is intended to stimulate and accelerate research in Europe and encourage new projects aimed at advancing current knowledge in diabetes.